C. Britten

发表

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

E. Van Cutsem, J. Tabernero, L. Paz-Ares, 2014, Clinical Cancer Research.

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

J. Tabernero, K. Kern, H. Soares, 2017, Targeted Oncology.

G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer

C. Britten, N. Bucher, N Bucher, 2008, British Journal of Cancer.

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

C. Britten, 2013, Cancer Chemotherapy and Pharmacology.

Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma

A. Bullock, M. Lowery, D. Ryan, 2019, Investigational New Drugs.

Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial.

Manish R. Patel, A. Ravaud, K. Kelly, 2016 .

The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors

Jeffrey W. Scott, Sunil Sharma, C. Britten, 2014, Cancer Chemotherapy and Pharmacology.

Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer

M. Erlander, A. Giordano, C. Britten, 2019, PloS one.

Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials

A. Yang, C. Britten, B. George, 2022, Cytotherapy.

Racial Differences in Stage IV Colorectal Cancer Survival in Younger and Older Patients

D. Rockey, A. Alberg, E. Hill, 2017, Clinical colorectal cancer.

Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study

A. Gomes, D. Elashoff, R. Finn, 2012, BMC Cancer.

Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay

D. V. Von Hoff, S. Hilsenbeck, C. Britten, 1999, Cancer Chemotherapy and Pharmacology.

Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC

P. Jänne, J. Engelman, J. Schellens, 2008 .

Clinical trial designs for targeted agents.

C. Britten, L. Siu, B. Ma, 2002, Hematology/oncology clinics of North America.

A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer.

J. Baselga, C. Britten, D. Demanse, 2012 .

A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors

Y. Zhuang, M. Thomas, C. Britten, 2017, Clinical Cancer Research.

Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients.

A. Gomes, J. Sayre, R. Finn, 2017, AJR. American journal of roentgenology.

Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.

M. Hidalgo, G. Weiss, C. Britten, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development and Validation of a Drug Activity Biomarker that Shows Target Inhibition in Cancer Patients Receiving Enzastaurin, a Novel Protein Kinase C-β Inhibitor

R. Herbst, M. Carducci, C. Britten, 2006, Clinical Cancer Research.

A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors

R. Finn, D. Camidge, C. Britten, 2008, Anti-cancer drugs.

A phase I dose escalation study of AUY922, a novel HSP90 inhibitor, in patients with advanced solid malignancies.

G. Shapiro, K. Bhalla, C. Britten, 2016, Journal of Clinical Oncology.

Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology

C. Britten, M. Subklewe, James H. Lewis, 2022, American journal of clinical oncology.

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors

M. von Mehren, Z. Wainberg, C. Britten, 2014, Investigational New Drugs.

Evaluation of the factors influencing the clearance of the novel thymidylate synthase inhibitor ZD9331

C. Britten, S. Baker, E. Douglass, 1999 .

A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077.

G. Weiss, D. V. Von Hoff, C. Britten, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

AUY922, a novel HSP90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies.

G. Shapiro, C. Britten, C. Sessa, 2010 .

Deforolimus trial 106- A Phase I trial evaluating 7 regimens of oral Deforolimus (AP23573, MK-8669)

A. Tolcher, W. Tap, C. Britten, 2008 .

Pharmacokinetics of oral deforolimus (AP23573, MK-8669)

A. Tolcher, W. Tap, C. Britten, 2008 .

Phase I a nd P harmacologic S tudy o f O SI-774, a n Epidermal G rowth F actor R eceptor T yrosine K inase Inhibitor, i n P atients W ith A dvanced S olid M alignancies

M. Hidalgo, J. Nemunaitis, C. Takimoto, 2001 .

A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors.

L. C. Chen, J. Baselga, J. Tabernero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A pilot study of IV bevacizumab in hepatocellular cancer patients undergoing chemoembolization

A. Gomes, R. Finn, C. Britten, 2005 .

A phase I dose-escalation and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced cancer.

R. Camidge, C. Britten, S. Leong, 2006, Journal of Clinical Oncology.

Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation

Sammy Saab, S. Raman, J. Hiatt, 2005, Hepatology.

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

E K Rowinsky, M. Hidalgo, A. Tolcher, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and Pharmacologic Study of the Human DNA Methyltransferase Antisense Oligodeoxynucleotide MG98 given as a 21-day Continuous Infusion Every 4 Weeks

E. Eisenhauer, K. Gelmon, M. Moore, 2003, Investigational New Drugs.

A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.

D. V. Von Hoff, C. Britten, S. Baker, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

C. Britten, A. Patnaik, L. Siu, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

J. Christensen, R. Finn, C. Britten, 2012, Molecular Cancer Therapeutics.

Preclinical Development Dacomitinib ( PF-00299804 ) , an Irreversible Pan-HER Inhibitor , Inhibits Proliferation of HER 2-Ampli fi ed Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

J. Christensen, R. Finn, C. Britten, 2012 .

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

A. Ravaud, K. Kelly, T. Stinchcombe, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer

J. Baselga, M. Ranson, J. Schellens, 2018, Cancer Chemotherapy and Pharmacology.

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma.

A. Tolcher, W. Tap, F. Haluska, 2013, Annals of Oncology.

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.

A. Ravaud, L. Dirix, C. Britten, 2018, The Lancet. Oncology.

366 Phase I Dose-escalation Study of the Oral Dual MTOR/PI3K Inhibitor BEZ235, Solid Dispersion System (SDS) Sachet Formulation, in Patients with Advanced Solid Tumors

J. Baselga, J. Schellens, M. Schuler, 2012 .

Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer

P. LoRusso, Z. Wainberg, C. Britten, 2014, Investigational New Drugs.

A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors.

J. Tabernero, R. Kurzrock, A. Stathis, 2012 .

Targeting ErbB receptor signaling: a pan-ErbB approach to cancer.

C. Britten, Carolyn D Britten, 2004, Molecular cancer therapeutics.

Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.

L. Denis, C. Britten, L. Siu, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer

C. Britten, A. Patnaik, C. Kollmannsberger, 2021, Investigational New Drugs.

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

P. Jänne, J. Engelman, J. Schellens, 2011, Clinical Cancer Research.

First-in-human study of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-00299804, a small molecule irreversible panHER inhibitor in patients with advanced cancer

J. Schellens, D. Camidge, C. Britten, 2007 .

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period

F. Kabbinavar, C. Baum, C. Britten, 2008, Cancer Chemotherapy and Pharmacology.

The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours

G. Shapiro, P. LoRusso, C. Britten, 2020, British journal of clinical pharmacology.

Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer

M. Thomas, M. Nishimura, S. Mehrotra, 2017, Journal of Hematology & Oncology.

Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model

R. Finn, C. Britten, R. Busuttil, 2009, Liver international : official journal of the International Association for the Study of the Liver.

Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin’s Lymphoma or Multiple Myeloma

J. Nemunaitis, C. Britten, D. Quinn, 2009, Clinical pharmacokinetics.

A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC–CTG) IND 130

K. Bélanger, K. Gelmon, L. Seymour, 2005, Investigational New Drugs.

First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors

G. Shapiro, K. Bhalla, C. Britten, 2013, Clinical Cancer Research.

Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer

H. Christofk, F. Kabbinavar, C. Britten, 2014, Journal of Cancer Research and Clinical Oncology.

Phase ib/2a study of PLX51107, a small molecule BET inhibitor, in subjects with advanced hematological malignancies and solid tumors.

C. Britten, A. Patnaik, Ben J. Powell, 2018 .

First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors

K. Gelmon, A. Tolcher, L. Denis, 2007, Clinical Cancer Research.

Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.

E K Rowinsky, S G Hilsenbeck, D. V. Von Hoff, 1999, Cancer research.

Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.

R. Herbst, M. Carducci, C. Britten, 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.

S. Soignet, P. Deutsch, C. Britten, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.

M. Hidalgo, D. V. Von Hoff, G. Clark, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting ErbB receptor interactions: A phase I trial of trastuzumab and erlotinib in metastatic HER2+ Breast Cancer.

L. Bosserman, R. Finn, C. Britten, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

750PPhase Ib study of PF-04136309 (an oral CCR2 inhibitor) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic adenocarcinoma

A. Bullock, M. Lowery, D. Ryan, 2017 .

Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): Pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study.

A. Ravaud, L. Dirix, C. Britten, 2017 .

Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.

A. Ravaud, K. Kelly, T. Stinchcombe, 2016 .

Biologic effects of CP-724,714, a selective HER-2/neu kinase inhibitor, on human breast cancer cells with variable expression of EGFR and HER-2

J. Dering, R. Finn, C. Britten, 2004 .

Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy

J. Egen, T. Arvedson, A. Coxon, 2021, Annual Review of Cancer Biology.

Avelumab in patients with metastatic urothelial carcinoma: Pooled results from two cohorts of the phase 1b JAVELIN Solid Tumor trial.

A. Ravaud, L. Dirix, C. Britten, 2017 .

A Phase I and Pharmacokinetic Study of the Mitochondrial-specific Rhodacyanine Dye Analog MKT 0771

G. Weiss, C. Britten, L. Smith, 2000 .

Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344

D. Townsend, K. Tew, C. Britten, 2016, The Journal of Pharmacology and Experimental Therapeutics.

321 POSTER A phase I trial evaluating pharmacodynamics of deforolimus (AP23573, MK-8669) delivered orally on multiple dosing schedules

T. Clackson, C. Britten, L. Berk, 2008 .

Automatic trial eligibility surveillance based on unstructured clinical data

Stéphane M. Meystre, Youngjun Kim, Paul M. Heider, 2019, Int. J. Medical Informatics.

A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach.

L. Bosserman, R. Finn, C. Britten, 2009, Clinical breast cancer.

Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase.

K. Wilner, G. Schwartz, C. Britten, 2010 .

Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers

H. Gabra, C. Britten, J. Bendell, 2017, Investigational New Drugs.

t(2;5) positive lymphoma with peripheral blood involvement.

R. Gascoyne, C. Britten, C. Britten, 1998, Leukemia & lymphoma.

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

C. Britten, A. Patnaik, L. Siu, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma.

A. Tolcher, W. Tap, F. Haluska, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of XL228, a potent IGF1R/AURORA/SRC inhibitor, in patients with solid tumors or hematologic malignancies.

H. Hurwitz, C. Britten, D. Clary, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of XL228, a multitargeted protein kinase inhibitor, in patients (pts) with solid tumors or multiple myeloma.

David C. Smith, H. Hurwitz, C. Britten, 2010 .